悪性リンパ腫治療による好中球減少に対してのG-CSF投与法の検討

概要

論文の詳細を見る
In Japan, the health insurance regulations state that it is necessary to start the administration of G-CSF for neutropenia caused by cancer chemotherapy after the neutropenia has appeared. Under these regulations however, in the case of malignant lymphoma, we can start to administer G-CSF at any time, except in the 24 hours before and after the chemotherapy. In the present study on malignant lymphoma, we found that it was more effective to administer G-CSF for the purpose of increasing the nadir of neutrophil counts early on rather than waiting for the appearance of neutropenia before starting its administration. We also noted that interrupting the administration of G-CSF for a day reduced the nadir of neutrophil counts. Further, in patients whose neutrophil counts were less than 100/μL developed sepsis more readily than those in whom neutrophil counts were more than 100/μL. As our conclusions, in malignant lymphoma patients, the continuous administration of G-CSF from the early stage can reduce the severity of neutropenia and such patients with severe neutropenia have an increased risk of sepsis.
日本医療薬学会の論文
2006-06-10